Longeveron (LGVN) Net Income towards Common Stockholders (2020 - 2026)
Longeveron's (LGVN) quarterly Net Income towards Common Stockholders came in at -$5.5 million in Q1 2026, up 14.64% year-on-year from -$4.8 million in Q1 2025, and down 1.86% quarter-over-quarter from -$5.4 million in Q4 2025.
Longeveron (LGVN) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Longeveron's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$5.5 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 14.64% year-over-year to -$5.5 million in Q1 2026; TTM through Mar 2026 was -$23.2 million, a 14.12% increase from a year earlier, with the FY2025 full-year figure at -$22.7 million, up 7.79% from the prior year.
- Net Income towards Common Stockholders retreated to -$5.5 million in Q1 2026 per LGVN's latest filing, from -$5.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$4.1 million in Q4 2024 and bottomed at -$42.7 million in Q1 2023.
- The 5-year median for Net Income towards Common Stockholders is -$5.4 million (2025), against an average of -$7.9 million.
- Across the five-year window, Net Income towards Common Stockholders plunged 942.87% in 2023 and soared 89.9% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$4.5 million in 2022, then sank by 35.25% to -$6.0 million in 2023, then surged by 32.3% to -$4.1 million in 2024, then slumped by 33.4% to -$5.4 million in 2025, then decreased by 1.86% to -$5.5 million in 2026.
- Per Business Quant, the three latest LGVN Net Income towards Common Stockholders figures stand at -$5.5 million (Q1 2026), -$5.4 million (Q4 2025), and -$7.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | -5.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -5.44 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -5.03 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Sep 30, 2024 | -4.57 Mn |
| Jun 30, 2024 | -11.91 Mn |
| Mar 31, 2024 | -4.31 Mn |
| Dec 31, 2023 | -6.03 Mn |
| Sep 30, 2023 | -5.90 Mn |
| Jun 30, 2023 | -5.63 Mn |
| Mar 31, 2023 | -42.72 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -5.24 Mn |
| Jun 30, 2022 | -4.92 Mn |
| Mar 31, 2022 | -4.10 Mn |
| Dec 31, 2021 | 44.90 Mn |
| Sep 30, 2021 | -22.91 Mn |
| Jun 30, 2021 | -20.06 Mn |